Edition:
United Kingdom

Biotechnology & Medical Research

Ultragenyx Announces Proposed Public Offering Of Common Stock

Jan 22 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ULTRAGENYX PHARMACEUTICAL - COMMENCED PUBLIC OFFERING OF UP TO $175 MILLION SHARES OF ITS COMMON STOCK.

Monday, 22 Jan 2018

Adamas Announces Proposed Public Offering Of Common Stock

Jan 22 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADAMAS PHARMACEUTICALS INC SAYS IT PLANS TO OFFER $85 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Monday, 22 Jan 2018

Poxel: Q4 Revenues At 5.2 Million Euros ‍​

Jan 22 (Reuters) - POXEL SA ::AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS WERE €53.4 MILLION ($64.1 MILLION).‍​.Q4 REVENUES OF €5.2 MILLION‍​.THE CASH BURN RATE DURING THE FOURTH QUARTER WAS IN LINE WITH THE COMPANY’S EXPECTATIONS.‍​.

Monday, 22 Jan 2018

Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men

Jan 22 (Reuters) - Nymox Pharmaceutical Corp ::NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN.NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH...

Monday, 22 Jan 2018

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.